LifeMD (LFMD) AI Stock Analysis

• Market Cap: $192.54M
• Dividend Yield: N/A
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: 30.71%
• EPS Growth: 73.43%
• Country: US
• Employees: 304
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -0.10
• Shares Outstanding: 48,135,883
• 10 Day Avg. Volume: 1,244,607
• 30 Day Avg. Volume: 1,200,437
• PEG Ratio: 0.44
• Price to Book (P/B): -37.17
• Price to Sales (P/S): 0.96
• P/FCF Ratio: 34.12
• Enterprise Value/Market Cap: 1.55
• Enterprise Value/Revenue: 1.18
• Enterprise Value/Gross Profit: 1.36
• Enterprise Value/Ebitda: 28.27
• 1Y Price Target: $9.67
• Price Target Upside: 141.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $4.00 ▲(0.00% Upside)

The score is held down primarily by weak profitability and balance-sheet risk metrics in the provided financial statement analysis, plus a longer-term bearish technical setup (below 50/100/200-day averages and negative MACD). These are partially offset by constructive earnings-call guidance and operational momentum (telehealth growth and rising adjusted EBITDA) alongside improving cash flow.

Positive Factors

Strategic pharmaceutical partnerships

Collaborations with major pharma give LifeMD durable access to branded GLP-1 therapies, improving product offering, patient acquisition and retention. These partnerships bolster clinical credibility, expand addressable market, and support sustained subscription and pharmacy revenue growth.

Regulatory approval for compounding pharmacy

Approval for a 503-A compounding pharmacy enables LifeMD to produce personalized medications at scale, improving vertical control of supply and margins. This structural capability supports differentiated services across chronic care and dermatology, lowering reliance on third parties long term.

Enhanced liquidity via revolving credit facility

A committed $30M revolver (expandable to $50M) materially improves financial flexibility for organic growth and potential M&A without immediate draw; this enhances medium-term resilience and capital allocation optionality while management retains cash buffers.

Negative Factors

Weak profitability margins

Despite strong gross margins, negative net margin and minimal EBIT leave limited internal funding for growth and require external capital or cost cuts. Sustained low profitability constrains reinvestment, increases vulnerability to sector shocks, and slows durable margin recovery.

Elevated leverage and balance-sheet risk

A high debt-to-equity ratio signals reliance on borrowings, raising interest, covenant and refinancing risks that limit strategic flexibility. Leverage magnifies downside in slower growth periods and can force conservative capital allocation over the next several quarters.

Competitive pressure in weight management

Persistent competition from low-cost compounded GLP-1 providers pressures pricing and retention in a core category. Even with pharma partnerships, long-term commoditization risks eroding margins and market share, challenging durable revenue mix and profitability improvement.

LifeMD Business Overview & Revenue Model

Company Description

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.

How the Company Makes Money

LifeMD generates revenue through several key streams, primarily by charging for telehealth consultations and subscription services. Patients can pay for one-time virtual visits or opt for monthly subscription plans that provide ongoing access to healthcare professionals and personalized treatment plans. Additionally, the company earns money from the sale of prescription medications through its online pharmacy, which allows for direct shipping to patients. Significant partnerships with pharmaceutical companies and health-related brands also contribute to LifeMD's earnings, as they often collaborate on marketing initiatives and product offerings, enhancing the company's service portfolio and revenue potential.

LifeMD Financial Statement Overview

Summary

LifeMD shows potential with revenue growth and strong gross profit margins. However, high debt levels, negative net profit margins, and financial instability due to significant leverage are concerning.

Income Statement

LifeMD shows a positive revenue growth trend with a 3.01% increase in TTM, indicating potential market expansion. However, the company struggles with profitability, as evidenced by a negative net profit margin of -2.25% and a low EBIT margin of 1.11%. The gross profit margin is strong at 91.64%, suggesting efficient cost management, but the net losses highlight ongoing challenges in achieving sustainable profitability.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 4.96, indicating significant leverage and potential financial risk. The return on equity is positive at 2.60%, showing some return on shareholder investment, but the low equity ratio suggests a weak capital structure. Overall, the balance sheet reflects financial instability and high reliance on debt financing.

Cash Flow

LifeMD's cash flow statement shows a positive free cash flow growth rate of 27.97%, indicating improved cash generation capabilities. The operating cash flow to net income ratio of 0.23 suggests moderate cash flow efficiency. However, the free cash flow to net income ratio of 1.29 indicates that free cash flow exceeds net income, which is a positive sign of cash flow health despite net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	252.34M	212.45M	152.55M	119.03M	92.88M	37.29M
Gross Profit	219.43M	188.39M	133.65M	100.37M	74.88M	28.43M
EBITDA	10.55M	-6.65M	-7.89M	-38.60M	-53.95M	-57.48M
Net Income	-4.60M	-18.88M	-20.60M	-45.54M	-60.90M	-58.65M
Balance Sheet
Total Assets	65.98M	72.46M	58.48M	25.67M	49.92M	13.40M
Cash, Cash Equivalents and Short-Term Investments	23.79M	35.00M	33.15M	3.96M	41.33M	9.18M
Total Debt	6.53M	25.10M	18.93M	4.13M	1.85M	1.06M
Total Liabilities	62.62M	76.51M	52.91M	32.97M	24.10M	14.22M
Stockholders Equity	1.31M	-5.49M	3.51M	-6.83M	26.85M	1.35M
Cash Flow
Free Cash Flow	16.98M	5.98M	86.95K	-35.83M	-36.49M	-12.53M
Operating Cash Flow	13.13M	17.51M	8.82M	-22.94M	-33.09M	-12.13M
Investing Cash Flow	-12.88M	-11.54M	-8.73M	-13.91M	-3.40M	-798.14K
Financing Cash Flow	-14.05M	-4.12M	29.10M	-528.20K	68.64M	21.00M

LifeMD Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFMD, the sentiment is Neutral. The current price of 4 is above the 20-day moving average (MA) of 3.55, below the 50-day MA of 4.16, and below the 200-day MA of 7.36, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 54.49 is Neutral, neither overbought nor oversold. The STOCH value of 76.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LFMD.

LifeMD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PETS	50 Neutral	$70.95M	-1.25	-78.89%	―	-24.81%	-5344.15%
LFMD	49 Neutral	$192.54M	-23.38	―	―	30.71%	73.43%
YI	37 Underperform	$24.64M	-2.55	―	―	-7.46%	73.05%

LifeMD Corporate Events

LifeMD Secures New Revolving Credit Facility for Growth

On January 2, 2026, LifeMD, Inc. entered into a senior secured revolving credit agreement with Citizens Bank, N.A. that provides a committed $30 million credit facility, with an accordion option to increase total availability to $50 million, maturing on January 2, 2029. The facility, which carries no upfront fee, is priced on a leverage-based grid using either Term SOFR plus 1.50%–2.25% or an Alternate Base Rate plus 0.50%–1.25%, with commitment fees of 0.225%–0.30% on unused amounts, and is backed by pledge, security and guarantee agreements from LifeMD and its subsidiaries. As of the January 2, 2026 closing, LifeMD had not drawn on the facility, indicating that existing cash and expected cash flow are currently sufficient to fund organic growth, while the new revolving line enhances the company’s financial flexibility for potential corporate development and shareholder value initiatives and subjects it to leverage and interest coverage covenants that will help shape its capital structure and growth strategy going forward.

The most recent analyst rating on (LFMD) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.

LifeMD Reschedules Q3 Earnings Call Amid Revenue Adjustments

On November 5, 2025, LifeMD announced the rescheduling of its third quarter 2025 earnings release and conference call to November 17, 2025, due to corrections identified in revenue recognition related to past data system migrations. The adjustments, impacting approximately $4.6 million or 1.4% of cumulative revenue, will not materially affect reported revenue results or the company’s cash flow and position. This decision reflects LifeMD’s commitment to accurate financial reporting and transparency, ensuring stakeholders are informed of the necessary adjustments without significant operational impact.

The most recent analyst rating on (LFMD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.

LifeMD Divests WorkSimpli Stake to Focus on Healthcare

On November 4, 2025, LifeMD, Inc. completed the sale of its majority interest in WorkSimpli Software LLC, valuing the company at approximately $65 million. This strategic divestiture allows LifeMD to focus on expanding its virtual care and pharmacy services, reinforcing its position as a pure-play healthcare company. The transaction, which involved a cash payment of $22 million at closing and potential additional earnings based on performance targets, is expected to strengthen LifeMD’s balance sheet and accelerate growth in its core business areas. The move is seen as a pivotal step in LifeMD’s transformation, enabling the company to concentrate on its primary healthcare offerings and expand into new clinical verticals.

The most recent analyst rating on (LFMD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.